scholarly journals High-level transgene expression mediated by the piggyBac transposon enhances transgenic therapeutic effects in cervical cancer xenografts

2010 ◽  
Author(s):  
Xu
Keyword(s):  
Cervical Cancer ◽  
Transgene Expression ◽  
Therapeutic Effects ◽  
Piggybac Transposon ◽  
High Level

scholarly journals Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system

2015 ◽  
Vol 2 (1) ◽  
pp. 96-105 ◽  
Author(s):  
Xiang Chen ◽  
Jing Cui ◽  
Zhengjian Yan ◽  
Hongmei Zhang ◽  
Xian Chen ◽  
...  
Keyword(s):  
Mammalian Cells ◽  
Transgene Expression ◽  
Piggybac Transposon ◽  
High Level ◽  
Expression In Mammalian Cells

scholarly journals Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Samira Sanami ◽  
Fatemeh Azadegan-Dehkordi ◽  
Mahmoud Rafieian-Kopaei ◽  
Majid Salehi ◽  
Maryam Ghasemi-Dehnoo ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
T Lymphocytes ◽  
Tertiary Structure ◽  
Therapeutic Vaccine ◽  
Epitope Prediction ◽  
Therapeutic Effects ◽  
Epitope Vaccine ◽  
In Vivo Experiments

AbstractCervical cancer, caused by human papillomavirus (HPV), is the fourth most common type of cancer among women worldwide. While HPV prophylactic vaccines are available, they have no therapeutic effects and do not clear up existing infections. This study aims to design a therapeutic vaccine against cervical cancer using reverse vaccinology. In this study, the E6 and E7 oncoproteins from HPV16 were chosen as the target antigens for epitope prediction. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) epitopes were predicted, and the best epitopes were selected based on antigenicity, allergenicity, and toxicity. The final vaccine construct was composed of the selected epitopes, along with the appropriate adjuvant and linkers. The multi-epitope vaccine was evaluated in terms of physicochemical properties, antigenicity, and allergenicity. The tertiary structure of the vaccine construct was predicted. Furthermore, several analyses were also carried out, including molecular docking, molecular dynamics (MD) simulation, and in silico cloning of the vaccine construct. The results showed that the final proposed vaccine could be considered an effective therapeutic vaccine for HPV; however, in vitro and in vivo experiments are required to validate the efficacy of this vaccine candidate.

scholarly journals The CD11b promoter directs high-level expression of reporter genes in macrophages in transgenic mice [published erratum appears in Blood 1995 Apr 1;85(7):1983]

Blood ◽  
1995 ◽  
Vol 85 (2) ◽  
pp. 319-329 ◽  
Author(s):  
S Dziennis ◽  
RA Van Etten ◽  
HL Pahl ◽  
DL Morris ◽  
TL Rothstein ◽  
...  
Keyword(s):  
Gene Expression ◽  
Transgenic Mice ◽  
Transgene Expression ◽  
Heterologous Gene Expression ◽  
Myeloid Cells ◽  
Reporter Genes ◽  
Regulatory Elements ◽  
Specific Expression ◽  
High Level

Abstract CD11b is the alpha chain of the Mac-1 integrin and is preferentially expressed in myeloid cells (neutrophils, monocytes, and macrophages). We have previously shown that the CD11b promoter directs cell-type- specific expression in myeloid lines using transient transfection assays. To confirm that these promoter sequences contain the proper regulatory elements for correct myeloid expression of CD11b in vivo, we have used the -1.7-kb human CD11b promoter to direct reporter gene expression in transgenic mice. Stable founder lines were generated with two different reporter genes, a Thy 1.1 surface marker and the Escherichia coli lacZ (beta-galactosidase) gene. Analysis of founders generated with each reporter demonstrated that the CD11b promoter was capable of driving high levels of transgene expression in murine macrophages for the lifetime of the animals. Similar to the endogenous gene, transgene expression was preferentially found in mature monocytes, macrophages, and neutrophils and not in myeloid precursors. These experiments indicate that the -1.7 CD11b promoter contains the regulatory elements sufficient for high-level macrophage expression. This promoter should be useful for targeting heterologous gene expression to mature myeloid cells.

scholarly journals Olanzapine-high potency antipsychotic drug inducing significant weight gain: A case report

2008 ◽  
Vol 136 (5-6) ◽  
pp. 284-288 ◽  
Author(s):  
Nadja Maric ◽  
Dragana Josifovic-Kostic ◽  
Olivera Vukovic ◽  
Dubravka Britvic ◽  
Miroslava Jasovic-Gasic
Keyword(s):  
Weight Gain ◽  
Psychotic Disorders ◽  
Vascular Diseases ◽  
Initial Response ◽  
Young Female ◽  
The Body ◽  
Average Weight ◽  
Therapeutic Effects ◽  
Significant Weight Gain ◽  
High Level

INTRODUCTION Olanzapine is a second generation antipsychotic (SGA) with a high level of therapeutic effectiveness in schizophrenia and other psychotic disorders. Along with the positive therapeutic effects, an increase of the body weight frequently occurs. According to the literature, the average weight gain is about 6-7 kg during several months of treatment. This could be valued as a moderate weight increase. CASE OUTLINE This article presents a case of a young female with schizophrenia, without clinical improvement with several antipsychotics (clozapine, risperidone, haloperidol) and with the occurrence of significant neurological side effects. The treatment started with olanzapine (baseline) was associated with good initial response (PANSS reduction 20% in the first two weeks) and the improvement was maintained further on (PANSS reduction 50% after 16 weeks). Significant increase (20 kg, 40%) in weight appeared during the following 16 weeks (BMI at baseline 17.9 kg/m2; BMI 16 weeks later 25.1 kg/m2). CONCLUSION High effectiveness of olanzapine in schizophrenia symptoms reduction was accompanied by a significant weight gain. However, this drug leads to impaired glucoregulation, dyslipidaemia etc. It also increases the risk of diabetes and cardio-vascular diseases, i.e. the main causes of mortality in schizophrenia after a suicide. Therefore, clinicians are suggested to focus on possible predictors of weight gain during olanzapine therapy, and act accordingly in order to prevent serious health consequences.

scholarly journals THE HERBAL MEDICINE CONTAINING OF IVY LEAF DRY EXTRACT IN THE TREATMENT OF PRODUCTIVE COUGH IN CHILDREN

2020 ◽  
Vol 73 (4) ◽  
pp. 668-673
Author(s):  
Magdalena Olszanecka-Glinianowicz ◽  
Zbigniew Doniec ◽  
Karina Schönknecht ◽  
Agnieszka Almgren-Rachtan
Keyword(s):  
Herbal Medicine ◽  
Good Alternative ◽  
Daily Activities ◽  
Therapeutic Effects ◽  
Productive Cough ◽  
Dry Extract ◽  
Outpatient Visits ◽  
Primary Health ◽  
Level Of Satisfaction ◽  
High Level

The aim: The assessment of the therapeutic effects of the herbal medicine containing of ivy leaf dry extract administered twice a day in children with productive cough and their guardians’ satisfaction with the use of this syrup. Material and methods: A multicenter, observational survey was conducted by 268 doctors working in Primary Health Care. The survey was conducted during two routine, consecutive outpatient visits (including first supplemented retrospectively) resulting from the needs of therapy. Results: The study group consisted of 5162 patients treated for productive cough with the herbal medicine containing of ivy leaf dry extract administered twice a day. In 75.7%, productive cough was intense, in 61.6% it occurred at night, in 49.8% it was very common (several times per hour), and in 62.7% it affected daily activity. Most often the syrup containing of ivy leaf dry extract was used in doses twice a day for 2 ml or 4 ml. During observation the percentage of children with intensive, very common, night and affected daily activities cough decreased significantly. Very satisfied with a therapeutic effect of the preparation containing of ivy leaf dry extract administered twice a day were 68.2% of children guardians. Conclusions: The use of the herbal medicine containing of ivy leaf dry extract administered twice a day may be a good alternative to current therapeutic regimens in the treatment of productive cough in children. This recommendation is supported by effectiveness comparable to other medicines and a high level of satisfaction with its use by patients and guardians of chidren.

High level of MT-MMP expression is associated with invasiveness of cervical cancer cells

1996 ◽  
Vol 65 (2) ◽  
pp. 209-213 ◽  
Author(s):  
Christine Gilles ◽  
Myriam Polette ◽  
Jacques Piette ◽  
Carine Munaut ◽  
Erik W. Thompson ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Cells ◽  
Cervical Cancer Cells ◽  
High Level

scholarly journals High-level transgene expression in induced pluripotent stem cell–derived megakaryocytes: correction of Glanzmann thrombasthenia

Blood ◽  
2014 ◽  
Vol 123 (5) ◽  
pp. 753-757 ◽  
Author(s):  
Spencer K. Sullivan ◽  
Jason A. Mills ◽  
Sevasti B. Koukouritaki ◽  
Karen K. Vo ◽  
Randolph B. Lyde ◽  
...  
Keyword(s):  
Transgene Expression ◽  
Pluripotent Stem Cell ◽  
Induced Pluripotent Stem Cell ◽  
Type I ◽  
Glanzmann Thrombasthenia ◽  
Key Points ◽  
Single Allele ◽  
Induced Pluripotent ◽  
Aavs1 Locus ◽  
High Level

Key Points When targeted to a single allele of the AAVS1 locus, the Gp1ba promoter drives a high level of expression specifically to megakaryocytes. Transgene rescue in iPSCs provides a model for the return of surface αIIbβ3 expression to near-normal levels in patients with type I GT.

scholarly journals Plasmid DNA-based Alphavirus Vaccines

Vaccines ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 29 ◽  
Author(s):  
Kenneth Lundstrom
Keyword(s):  
Tumor Cells ◽  
Plasmid Dna ◽  
Transgene Expression ◽  
Tumor Regression ◽  
Infectious Agents ◽  
Application Range ◽  
Mammalian Cell Lines ◽  
High Level ◽  
Rna Replicon

Alphaviruses have been engineered as vectors for high-level transgene expression. Originally, alphavirus-based vectors were applied as recombinant replication-deficient particles, subjected to expression studies in mammalian and non-mammalian cell lines, primary cell cultures, and in vivo. However, vector engineering has expanded the application range to plasmid DNA-based delivery and expression. Immunization studies with DNA-based alphavirus vectors have demonstrated tumor regression and protection against challenges with infectious agents and tumor cells in animal tumor models. The presence of the RNA replicon genes responsible for extensive RNA replication in the RNA/DNA layered alphavirus vectors provides superior transgene expression in comparison to conventional plasmid DNA-based expression. Immunization with alphavirus DNA vectors revealed that 1000-fold less DNA was required to elicit similar immune responses compared to conventional plasmid DNA. In addition to DNA-based delivery, immunization with recombinant alphavirus particles and RNA replicons has demonstrated efficacy in providing protection against lethal challenges by infectious agents and tumor cells.

Sign in / Sign up

Export Citation Format

Share Document